<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474630</url>
  </required_header>
  <id_info>
    <org_study_id>NB-304</org_study_id>
    <secondary_id>COR-Diabetes</secondary_id>
    <nct_id>NCT00474630</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine whether the combination of naltrexone SR and bupropion
      SR is safe and effective in treating obesity in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal care of patients with diabetes mellitus includes vigorous and persistent efforts to
      achieve physiologic control of blood glucose as well as other often associated conditions
      including hypertension, dyslipidemia and excess weight. Pharmacologic interventions for the
      treatment of obesity in type 2 diabetes have shown significant reductions in HbA1c. Two Phase
      II clinical trials demonstrated that a combination of bupropion SR and naltrexone is
      associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in
      subjects with uncomplicated obesity. The current study investigated the safety and efficacy
      of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects
      with type 2 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary: Body Weight- Mean Percent Change</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c Levels</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides Levels, Using Log-transformed Data</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting HDL Cholesterol Levels</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose Levels</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight- Proportion of Subjects With ≥10% Decrease</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c- Proportion of Subjects With HbA1c &lt;7% at Endpoint</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Requiring Rescue Medications for Diabetes</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Dose Increase in Oral Antidiabetes Medications</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR Levels, Using Log-transformed Data</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>HOMA-IR= Homeostasis Model Assessment-Insulin Resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin Levels, Using Log-transformed Data</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c- Proportion of Subjects With HbA1c &lt;6.5% at Endpoint</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IWQOL-Lite Total Scores</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Discontinuing Due to Poor Glycemic Control</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting LDL Cholesterol Levels</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IDS-SR Total Scores</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Food Craving Inventory Sweets Subscale Score</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Food Craving Inventory Carbohydrates Subscale Score</measure>
    <time_frame>Baseline, 56 weeks</time_frame>
    <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">505</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>NB32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with ancillary therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone SR 32 mg/bupropion SR 360 mg/ day</intervention_name>
    <arm_group_label>NB32</arm_group_label>
    <other_name>NB32</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Ancillary therapy</intervention_name>
    <description>Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling</description>
    <arm_group_label>NB32</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subjects aged 18 to 70 years of age (inclusive)

          -  Body mass index (BMI) ≥27 and ≤45 kg/m²

          -  Diagnosed with type 2 diabetes mellitus and on no injectable antidiabetes medication
             or inhaled insulin for more than 3 months prior to randomization

          -  Took stable doses of oral single or combination hypoglycemic medications (biguanides,
             thiazolidinediones, meglitinides, α-glucosidase inhibitors, sulfonylureas, DPP4
             inhibitors) for at least 3 months prior to randomization or did not take medications
             for the treatment of type 2 diabetes mellitus

          -  Normotensive (systolic ≤145 mm Hg and diastolic ≤95 mm Hg). Antihypertensive
             medications were allowed with the exception of alpha-adrenergic blockers, and
             clonidine. Antihypertensive treatment was stable for at least 4 weeks prior to
             randomization.

          -  Medications for the treatment of dyslipidemia were allowed with the exception of
             cholestyramine and cholestypol as long as the medical regimen had been stable for at
             least 4 weeks prior to randomization.

          -  Free of opioid medication for 7 days prior to randomization

          -  HbA1c between 7% and 10%, fasting blood glucose &lt;270 mg/dL, and fasting triglycerides
             &lt;400 mg/dL

          -  No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN),
             bilirubin, calcium, and phosphorus

          -  Creatinine levels were ≤1.4 mg/dL for female subjects and ≤1.5 mg/dL for male subjects

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were within
             2.5 × upper limit of laboratory normal range (ULN)

          -  No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC
             differential, or platelets

          -  No clinically significant abnormality on urinalysis

          -  TSH within normal limits or normal T3, if TSH is below normal limits

          -  Female subjects of childbearing potential had a negative serum pregnancy test

          -  Negative urine drug screen

          -  An IDS-SR score &lt;2 on individual items 5 (sadness), 6 (irritability), 7
             (anxiety/tension), and 18 (suicidality) and an IDS-SR total score &lt;30

          -  Female subjects of childbearing potential were non-lactating and agreed to continue to
             use effective contraception throughout the study and 30 days after discontinuation of
             study drug

          -  Able to comply with all required study procedures and schedule

          -  Able to speak and read English

          -  Provided written informed consent

        Exclusion Criteria:

          -  Type I diabetes mellitus

          -  &quot;Brittle-diabetes&quot; or any hospitalization or emergency room visit due to poor diabetic
             control within 6 months prior to screening, history of diabetes-related dehydration
             leading to hospitalization, or history or evidence of ketoacidosis

          -  Obesity of known endocrine origin other than diabetes mellitus (e.g., untreated
             hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)

          -  Diabetes mellitus secondary to pancreatitis or pancreatectomy

          -  Serious medical condition including but not limited to renal or hepatic insufficiency
             and Class III or IV congestive heart failure; history of myocardial infarction, angina
             pectoris, claudication, or acute limb ischemia within 6 months prior to screening;
             lifetime history of stroke

          -  History of malignancy with exception of non-melanoma skin cancer or surgically cured
             cervical cancer within 5 years prior to screening

          -  Loss or gain of more than 5.0 kg within the 3 months prior to screening

          -  Severe microvascular or macrovascular complications of diabetes, including but not
             limited to proliferative retinopathy, active limb ulcerations, amputation of
             metatarsals or above

          -  Serious psychiatric illness, including lifetime history of bipolar disorder,
             schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious
             personality disorder (e.g., borderline or antisocial); current severe major depressive
             disorder; recent (6 months prior to screening) suicide attempt or current active
             suicidal ideation; or recent hospitalization due to psychiatric illness

          -  Response to the bipolar disorder questions that indicated the presence of bipolar
             disorder

          -  Required medications for the treatment of a psychiatric disorder (with the exception
             of short term insomnia) within 6 months prior to screening

          -  History of drug or alcohol abuse or dependence within 1 year prior to screening

          -  Baseline ECG with a QTc interval (Bazett's formula) &gt;450 msec (men) and &gt;470 msec
             (women) or the presence of any clinically significant cardiac abnormalities, including
             but not limited to patterns consistent with recent myocardial ischemia, electrolyte
             abnormalities, or atrial or ventricular dysrhythmia or significant conduction
             abnormalities

          -  Received the following excluded concomitant medications: any psychotropic agents
             (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant
             agents, and agents for the treatment of attention deficit disorder) with the exception
             of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2
             mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any
             anorectic or weight loss agents; any over-the-counter dietary supplements or herbs
             with psychoactive, appetite, or weight effects; alpha-adrenergic blockers; dopamine
             agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids;
             cholestyramine, cholestypol, Depo Provera®; smoking cessation agents; use of opioid or
             opioid-like medications, including analgesics and antitussives

          -  History of surgical or device intervention for obesity (e.g., gastric banding)

          -  History of seizures of any etiology, or of predisposition to seizures (e.g., history
             of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness,
             concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural
             hematoma, or febrile seizures)

          -  Treatment with bupropion or naltrexone within 12 months prior to screening

          -  History of hypersensitivity or intolerance to bupropion or naltrexone

          -  Changes in smoking status or in tobacco or nicotine use within 3 months prior to
             screening or planned during study participation

          -  Participated in a weight loss management program within one month prior to
             randomization

          -  Females who were pregnant or breast-feeding or planned to become pregnant during the
             study period or within 30 days of discontinuing study drug

          -  Planned surgical procedure that could impact the conduct of the study

          -  Received any investigational drug or used an experimental device or procedure within
             the previous 30 days

          -  Participated in any previous clinical trial conducted by Orexigen

          -  Had any condition that in the opinion of the investigator made the subject unsuitable
             for inclusion into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SelfCenter, PC</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthStar Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>98608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Medical Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Clinical Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research Institue</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCFP Inc.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSRA Partners in Health, Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Indiana Center for Clinical Research</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-Marc</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trover Center for Clinical Studies</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Institute</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Trends Research, LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twin Cities Clinical Research</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Nutrition and Metabolic Diseases, Univ. of Nevada</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology &amp; Diabetes Consultants</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes care and Information Center</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Medical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Ohio Nutrition Center, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wells Institute for Health Awareness</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Your Diabetes Endocrine and Nutrition Group</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29349</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cooper Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center of the Southwest</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVisions Consultants, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Research Associates, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Internal Medicine</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21. Erratum in: Diabetes Care. 2014 Feb;37(2):587.</citation>
    <PMID>24144653</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>October 10, 2014</results_first_submitted>
  <results_first_submitted_qc>November 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2014</results_first_posted>
  <disposition_first_submitted>October 25, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 25, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 31, 2012</disposition_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NB32</title>
          <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drug noncompliance, other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>NB32</title>
          <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="335"/>
            <count group_id="B2" value="170"/>
            <count group_id="B3" value="505"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.02" spread="9.05"/>
                    <measurement group_id="B2" value="53.46" spread="9.83"/>
                    <measurement group_id="B3" value="53.83" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.22" spread="18.93"/>
                    <measurement group_id="B2" value="105.08" spread="16.99"/>
                    <measurement group_id="B3" value="104.51" spread="18.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.40" spread="4.75"/>
                    <measurement group_id="B2" value="36.40" spread="4.50"/>
                    <measurement group_id="B3" value="36.40" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-primary: Body Weight- Mean Percent Change</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT (Full Analysis Set): Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary: Body Weight- Mean Percent Change</title>
          <population>Modified ITT (Full Analysis Set): Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of body weight</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.03" spread="0.34"/>
                    <measurement group_id="O2" value="-1.75" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.34</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c Levels</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/bupropion SR 360 mg/ day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Levels</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.07"/>
                    <measurement group_id="O2" value="-0.14" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.53" lower_limit="38.54" upper_limit="50.51"/>
                    <measurement group_id="O2" value="18.87" lower_limit="12.79" upper_limit="24.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>5.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Triglycerides Levels, Using Log-transformed Data</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Triglycerides Levels, Using Log-transformed Data</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.20" lower_limit="-15.59" upper_limit="-6.58"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-6.95" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting HDL Cholesterol Levels</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting HDL Cholesterol Levels</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.49"/>
                    <measurement group_id="O2" value="-0.29" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>4.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Blood Glucose Levels</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose Levels</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.87" spread="2.70"/>
                    <measurement group_id="O2" value="-4.02" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.21</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" spread="0.47"/>
                    <measurement group_id="O2" value="-2.89" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.57</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight- Proportion of Subjects With ≥10% Decrease</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight- Proportion of Subjects With ≥10% Decrease</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.49" lower_limit="13.82" upper_limit="23.16"/>
                    <measurement group_id="O2" value="5.66" lower_limit="2.07" upper_limit="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c- Proportion of Subjects With HbA1c &lt;7% at Endpoint</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c- Proportion of Subjects With HbA1c &lt;7% at Endpoint</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.14" lower_limit="37.61" upper_limit="50.68"/>
                    <measurement group_id="O2" value="26.28" lower_limit="18.91" upper_limit="33.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Requiring Rescue Medications for Diabetes</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Requiring Rescue Medications for Diabetes</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.26" lower_limit="19.05" upper_limit="29.91"/>
                    <measurement group_id="O2" value="35.22" lower_limit="29.81" upper_limit="45.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" lower_limit="0.28" upper_limit="3.87"/>
                    <measurement group_id="O2" value="1.26" lower_limit="0.00" upper_limit="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>7.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Dose Increase in Oral Antidiabetes Medications</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With Dose Increase in Oral Antidiabetes Medications</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="1.06" upper_limit="5.58"/>
                    <measurement group_id="O2" value="1.26" lower_limit="0.00" upper_limit="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>12.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR Levels, Using Log-transformed Data</title>
        <description>HOMA-IR= Homeostasis Model Assessment-Insulin Resistance</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR Levels, Using Log-transformed Data</title>
          <description>HOMA-IR= Homeostasis Model Assessment-Insulin Resistance</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.56" lower_limit="-27.77" upper_limit="-12.62"/>
                    <measurement group_id="O2" value="-14.67" lower_limit="-24.69" upper_limit="-3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.89</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin Levels, Using Log-transformed Data</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin Levels, Using Log-transformed Data</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.48" lower_limit="-19.70" upper_limit="-6.78"/>
                    <measurement group_id="O2" value="-10.35" lower_limit="-18.75" upper_limit="-1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.13</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c- Proportion of Subjects With HbA1c &lt;6.5% at Endpoint</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c- Proportion of Subjects With HbA1c &lt;6.5% at Endpoint</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.72" lower_limit="15.39" upper_limit="26.05"/>
                    <measurement group_id="O2" value="10.22" lower_limit="5.15" upper_limit="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IWQOL-Lite Total Scores</title>
        <description>IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IWQOL-Lite Total Scores</title>
          <description>IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" spread="0.70"/>
                    <measurement group_id="O2" value="7.90" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.91" lower_limit="-29.29" upper_limit="-11.54"/>
                    <measurement group_id="O2" value="-13.29" lower_limit="-24.94" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.62</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Discontinuing Due to Poor Glycemic Control</title>
        <description>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Discontinuing Due to Poor Glycemic Control</title>
          <description>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control.</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">There were no subjects in the NB32 group that discontinued due to poor glycemic control.</measurement>
                    <measurement group_id="O2" value="1.89" lower_limit="0.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire</title>
        <description>Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire</title>
          <description>Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.89" spread="1.39"/>
                    <measurement group_id="O2" value="-6.91" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.22</ci_lower_limit>
            <ci_upper_limit>-0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting LDL Cholesterol Levels</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting LDL Cholesterol Levels</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.94"/>
                    <measurement group_id="O2" value="-0.01" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.48</ci_lower_limit>
            <ci_upper_limit>4.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.70"/>
                    <measurement group_id="O2" value="-1.12" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.47"/>
                    <measurement group_id="O2" value="-1.47" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IDS-SR Total Scores</title>
        <description>IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IDS-SR Total Scores</title>
          <description>IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.33"/>
                    <measurement group_id="O2" value="-1.60" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Food Craving Inventory Sweets Subscale Score</title>
        <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Food Craving Inventory Sweets Subscale Score</title>
          <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="0.28"/>
                    <measurement group_id="O2" value="-2.40" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Food Craving Inventory Carbohydrates Subscale Score</title>
        <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
        <time_frame>Baseline, 56 weeks</time_frame>
        <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>NB32</title>
            <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Food Craving Inventory Carbohydrates Subscale Score</title>
          <description>The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).</description>
          <population>Modified ITT: Included all subjects who were randomized, had a baseline weight measurement, and had at least one post-baseline weight measurement while on study drug. Missing data were imputed with the LOCF method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.26"/>
                    <measurement group_id="O2" value="-1.52" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>96</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, 56 weeks</time_frame>
      <desc>The safety analysis set includes all randomized subjects who took study drug and were assessed by investigator after their first dose, whether or not they discontinue the study. Treatment-emergent adverse events were defined as events that started or worsened in the double-blind treatment phase after the first dose and before 7 days post last dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>NB32</title>
          <description>Naltrexone SR 32 mg/Bupropion SR 360 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="69" subjects_affected="59" subjects_at_risk="333"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="52" subjects_at_risk="333"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="333"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="196" subjects_affected="141" subjects_at_risk="333"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="80" subjects_affected="61" subjects_at_risk="333"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="333"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="333"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="333"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="333"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="333"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="25" subjects_at_risk="333"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="333"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="333"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="52" subjects_affected="39" subjects_at_risk="333"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="53" subjects_affected="46" subjects_at_risk="333"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="333"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="37" subjects_at_risk="333"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="333"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI’s study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Head of Global Development</name_or_title>
      <organization>Orexigen Therapeutics, Inc.</organization>
      <phone>(858) 875-8600</phone>
      <email>MedInfo@Orexigen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

